2667 related items for PubMed ID: 20089952
1. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
[Abstract] [Full Text] [Related]
2. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
[Abstract] [Full Text] [Related]
3. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L, FTY720D2201 Study Group.
Mult Scler; 2010 Feb 04; 16(2):197-207. PubMed ID: 20028707
[Abstract] [Full Text] [Related]
4. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B, Ross AP, Tobias K.
Int J Clin Pract; 2011 Aug 04; 65(8):887-95. PubMed ID: 21679286
[Abstract] [Full Text] [Related]
5. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L, FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group.
Arch Neurol; 2012 Oct 04; 69(10):1259-69. PubMed ID: 22751847
[Abstract] [Full Text] [Related]
6. Fingolimod for relapsing multiple sclerosis: an update.
Horga A, Castilló J, Montalban X.
Expert Opin Pharmacother; 2010 May 04; 11(7):1183-96. PubMed ID: 20367536
[Abstract] [Full Text] [Related]
7. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
Lancet Neurol; 2012 May 04; 11(5):420-8. PubMed ID: 22494956
[Abstract] [Full Text] [Related]
8. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group.
N Engl J Med; 2010 Feb 04; 362(5):416-26. PubMed ID: 20089960
[Abstract] [Full Text] [Related]
9. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L, FTY720 D2201 Study Group.
Neurology; 2009 Jan 06; 72(1):73-9. PubMed ID: 19122034
[Abstract] [Full Text] [Related]
10. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
Lancet Neurol; 2014 Jun 06; 13(6):545-56. PubMed ID: 24685276
[Abstract] [Full Text] [Related]
11. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.
Expert Rev Neurother; 2011 Feb 06; 11(2):165-83. PubMed ID: 21158700
[Abstract] [Full Text] [Related]
12. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group.
N Engl J Med; 2006 Sep 14; 355(11):1124-40. PubMed ID: 16971719
[Abstract] [Full Text] [Related]
13. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ.
Clin Ther; 2006 Apr 14; 28(4):461-74. PubMed ID: 16750460
[Abstract] [Full Text] [Related]
14. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA, Weinstock-Guttman B.
Adv Ther; 2011 Apr 14; 28(4):270-8. PubMed ID: 21394595
[Abstract] [Full Text] [Related]
15. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
Agashivala N, Kim E.
Clin Ther; 2012 Jul 14; 34(7):1583-90. PubMed ID: 22749258
[Abstract] [Full Text] [Related]
16. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, DEFINE Study Investigators.
N Engl J Med; 2012 Sep 20; 367(12):1098-107. PubMed ID: 22992073
[Abstract] [Full Text] [Related]
17. Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS, TEMSO Trial Group.
N Engl J Med; 2011 Oct 06; 365(14):1293-303. PubMed ID: 21991951
[Abstract] [Full Text] [Related]
18. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T.
Arch Neurol; 2012 Feb 06; 69(2):262-4. PubMed ID: 22332194
[Abstract] [Full Text] [Related]
19. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
[Abstract] [Full Text] [Related]
20. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
Mult Scler; 2010 Jul 02; 16(7):848-54. PubMed ID: 20488825
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
